Hepatocellular Carcinoma Panel

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

AFP

AFP is used as a tumor marker to help detect and diagnose cancers of the liver, testes, and ovaries. Though the test is often ordered to monitor people with chronic liver diseases such as cirrhosis, chronic hepatitis B or hepatitis C because they have an increased lifetime risk of developing liver cancer. If a person has been diagnosed with hepatocellular carcinoma or another form of AFP-producing cancer, an AFP test may be ordered periodically to help monitor the person's response to therapy and to monitor for cancer recurrence.

AFP-L3

An AFP-L3% is sometimes also ordered to compare the amount of the AFP variant called AFP-L3 to the total amount of AFP. The test is used to help evaluate the risk of developing hepatocellular carcinoma, especially in those with chronic liver disease, and also to evaluate response of hepatocellular carcinoma to treatment.

Dcp (Des Gamma Carboxy

*Important Information on Lab Test Processing Times: Ulta Lab Tests is committed to informing you about the processing times for your lab tests processed through Quest Diagnostics. Please note that the estimated processing time for each test, indicated in business days, is based on data from the past 30 days across the 13 Quest Diagnostics laboratories for each test. These estimates are intended to serve as a guide and are not guarantees. Factors such as laboratory workload, weather conditions, holidays, and the need for additional testing or maintenance can influence actual processing times. We aim to offer estimates to help you plan accordingly. Please understand that these times may vary, and processing times are not guaranteed. Thank you for choosing Ulta Lab Tests for your laboratory needs.

The Hepatocellular Carcinoma Panel test contains 1 test with 3 biomarkers.

HCC Risk Panel includes serum AFP-L3%, total AFP and DCP. The combined measurement helps discriminate benign and malignant conditions related to primary liver diseases [1-4]. Furthermore, the combination measurement of three HCC biomarkers can identify a greater number of patients at risk of developing HCC than with each marker alone.

Customer Reviews